Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), founded in 2013, is a clinical stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare genetic diseases caused by premature termination codons nonsense mutations.
The Company has unique solutions which addresses the unmet needs of patients that today have no alternative solutions. The firm has an experienced management team with an impressive track record in the orphan drug space as well as an impressive list of existing investors. The Company has been listed on the NASDAQ since April 2018 after it completed an underwritten public offering.
The Company’s headquarters are in Waltham, Massachusetts with R&D operations in Rehovot, Israel.